IP Library Granted Patent US 9,907,886
Granted Patent B2
US 9,907,886 · App. 15/075,406 · Granted Mar 6, 2018

Drug-eluting medical implants

Inventors: Maria Palasis (Wellesley, MA); Changcheng You (Northbridge, MA); Danny Concagh (Medfield, MA); Lee Core (Needham, MA); Kicherl Ho (Groton, MA); Upma Sharma (Somerville, MA); Gregory T. Zugates (Chelmsford, MA)
Assignee: 480 BIOMEDICAL, INC.
A61L31/16A61F2/04A61F2/86A61F2/90A61K31/337A61L31/06A61L31/10A61L31/148D04C1/06A61F2210/0004A61F2210/0057A61F2230/0054A61F2250/0067A61K9/0024A61L2300/216A61L2300/416A61L2420/06A61L2420/08D10B2403/0112D10B2509/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,907,886
App. No.
15/075,406
Granted
Mar 6, 2018
Kind
B2
Abstract

Disclosed are self-expanding medical implants for placement within a lumen of a patient. The implants comprise a woven or non-woven structure having a substantially tubular configuration, and are designed to be low-profile such that they are deliverable with a small diameter catheter. The implants have a high recoverability and desired mechanical properties.

Claims (34)

1. A medical implant comprising:

a tubular structure comprising struts and open spaces between adjacent said struts, wherein said tubular structure is biostable

a first conformal coating comprising paclitaxel and a first polymeric material at least partially coating said struts;

wherein said tubular structure is characterized by a surface area of from 11.4 to 53.8 mm2/mm length of the tubular structure, and the amount of paclitaxel is within the range of about 0.002 to about 0.175 micrograms per square millimeter of said surface area; and

wherein the paclitaxel is the sole therapeutic agent in the medical implant.

2. The medical implant of claim 1 , wherein the amount of paclitaxel is within the range of about 0.002 to about 0.09 micrograms per square millimeter of said surface area.

3. The medical implant of claim 1 , wherein the amount of paclitaxel is within the range of about 0.003 to about 0.12 micrograms per square millimeter of said surface area.

4. The medical implant of claim 1 , wherein the amount of paclitaxel is within the range of about 0.004 to about 0.175 micrograms per square millimeter of said surface area.

5. The medical implant of claim 1 , wherein said tubular structure comprises a total amount of paclitaxel within the range of about 0.1 to about 2.0 micrograms per millimeter of length of said tubular structure.

6. The medical implant of claim 5 , wherein said tubular structure comprises a total amount of paclitaxel within the range of about 0.2 to about 2.0 micrograms per millimeter of length of said tubular structure.

7. The medical implant of claim 1 , further comprising a second conformal coating at least partially coating said first conformal coating, said second conformal coating comprising a second polymeric material.

8. The medical implant of claim 7 , wherein each of the first and second polymeric materials is biodegradable.

9. The medical implant of claim 7 , wherein said second conformal coating has a thickness up to 8 microns.

10. A medical implant comprising:

a tubular structure comprising struts and open spaces between adjacent said struts, wherein said tubular structure is biostable;

a first conformal coating comprising a first polymeric material and at least partially coating said struts; and

a second conformal coating at least partially coating said first conformal coating, said second conformal coating comprising a second polymeric material and paclitaxel as a single therapeutic agent in said medical implant;

wherein said tubular structure is characterized by a surface area, and the amount of paclitaxel is within the range of about 0.002 to about 0.175 micrograms per square millimeter of said surface area.

11. The medical implant of claim 10 , further comprising a third conformal coating at least partially coating said second conformal coating, said third conformal coating comprising a third polymeric material.

12. The medical implant of claim 11 , wherein each of the first, second and third polymeric materials is biodegradable.

13. The medical implant of claim 12 , wherein said third conformal coating has a thickness up to 8 microns.

14. The medical implant of claim 10 , wherein said tubular structure comprises a total amount of paclitaxel within the range of about 0.1 to about 2.0 micrograms per millimeter length of said tubular structure.

15. The medical implant of claim 14 , wherein the amount of paclitaxel is within the range of about 0.002 to about 0.02 micrograms per square millimeter of said surface area.

16. The medical implant of claim 10 , wherein said tubular structure comprises a total amount of paclitaxel within the range of about 0.2 to about 2.0 micrograms per millimeter of length of said tubular structure.

17. A medical implant comprising:

a tubular structure comprising struts and open spaces between adjacent said struts, wherein said tubular structure is biostable;

a first conformal coating comprising a first polymeric material and at least partially coating said struts; and

a second conformal coating at least partially coating said first conformal coating, said second conformal coating comprising a second polymeric material and an amount of paclitaxel as a single therapeutic agent in said medical implant;

wherein said tubular structure is characterized by a surface area, wherein the amount of paclitaxel is within the range of about 0.002 to about 0.175 micrograms per square millimeter of said surface area, and wherein said tubular structure has a surface area within the range of about 11.4 to about 53.8 square millimeters per millimeter length of said tubular structure.

18. The medical implant of claim 17 , wherein said tubular structure comprises a total amount of paclitaxel within the range of about 0.1 to about 2.0 micrograms per millimeter length of said tubular structure.

19. The medical implant of claim 17 , wherein said tubular structure comprises a total amount of paclitaxel within the range of about 0.2 to about 2.0 micrograms per millimeter of length of said tubular structure.

20. The medical implant of claim 17 , wherein the amount of paclitaxel is within the range of about 0.002 to about 0.02 micrograms per square millimeter of said surface area.

21. The medical implant of claim 17 , further comprising a third conformal coating at least partially coating said second conformal coating, said third conformal coating comprising a third polymeric material.

22. The medical implant of claim 21 , wherein each of the first, second and third polymeric materials is biodegradable.

Assignments (2)
CHANGE OF NAME Recorded Jan 17, 2020
From: 480 BIOMEDICAL, INC.
To: LYRA THERAPEUTICS, INC.
Reel/Frame 051637/0116 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2016
From: PALASIS, MARIA; YOU, CHANGCHENG; CONCAGH, DANNY; CORE, LEE; HO, KICHERL; SHARMA, UPMA; ZUGATES, GREGORY
To: 480 BIOMEDICAL, INC.
Reel/Frame 038058/0571 →
Continuity (13)
Continuation 15000605 · Jan 19, 2016
Continuation 14102945 · Dec 11, 2013
Continuation In Part 13891574 · May 10, 2013
Continuation In Part 13863632 · Apr 16, 2013
Continuation In Part 13766294 · Feb 13, 2013
Continuation In Part 13253720 · Oct 5, 2011
Continuation In Part 13183104 · Jul 14, 2011
Continuation In Part 13032281 · Feb 22, 2011
Continuation In Part 12783261 · May 19, 2010
Provisional Application 61624607 · Apr 16, 2012
Provisional Application 61179834 · May 20, 2009
Provisional Application 61251984 · Oct 15, 2009
Related Publication 20160271302A1 · Sep 22, 2016